Journal
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Volume 1865, Issue 1, Pages 90-100Publisher
ELSEVIER
DOI: 10.1016/j.bbcan.2015.12.001
Keywords
Adoptive cell transfer; Cancer immunotherapy; Genetically modified T cells; Clinical results; Toxicities; Pharmacokinetics/pharmacodynamics
Categories
Ask authors/readers for more resources
Adoptive cell transfer of T cells genetically modified with tumor-reactive chimeric antigen receptors (CARS) is a rapidly emerging field in oncology, which in preliminary clinical trials has already shown striking antitumor efficacy. Despite these premises, there are still a number of open issues related to CAR-T cells, spanning from their exact mechanism of action (pharmacodynamics), to the factors associated with their in vivo persistence ( pharmacokinetics), and, finally, to the relative contribution of each of the two in determining the antitumor effects and accompanying toxicities. In light of the unprecedented curative potential of CAR-T cells and of their predicted wide availability in the next few years, in this review we will summarize the current knowledge on the clinical pharmacology aspects of what is anticipated to be a brand new class of biopharmaceuticals to join the therapeutic armamentariurn of cancer doctors. (C) 2015 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available